Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

Fig. 2

Survival outcomes. a Investigator-assessed progression-free survival (PFS) in the overall population. b Overall survival (OS) in the overall population. The hazard ratio was estimated with the use of the Cox proportional-hazards model with stratification according to visceral metastatic disease (yes vs. no), menopausal status (pre-, peri- or postmenopausal), and sensitivity to prior endocrine therapy (yes vs. no)

Back to article page